EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies

Asfand Yar Cheema, Hossam M Ali, Bibi Maryam, Muhammad Faisal Aslam, Praveena S Thiagarajan, Daniyal Shahid, Mishaal Munir, Ali Najam, Shahzad Raza, Faiz Anwer

Transplantation and Cellular Therapy · 2026

DOI: 10.1016/j.jtct.2025.09.044 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplantation and Cellular Therapy, 2026. Verfasst von Asfand Yar Cheema und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Fairview Hospital, Cleveland, Ohio. Electronic address: Cheemaa@ccf.org. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric Antigen Receptor T cell (CAR-T) therapy has transformed the treatment of hematological malignancies. Autologous CAR-T therapies have shown remarkable efficacy but face multiple challenges, including the need to collect autologous T cell lymphocytes, logistical complexity, prolonged manufacturing time, inadequate quantity due to the collection of already exhausted cells from heavily treated patients, T cell quality not meeting the FDA specifications, and high costs, thereby limiting their widespread use. Allogeneic CAR-T (allo-CAR-T) therapy offers a promising alternative and several advantages, including immediate availability as an off-the-shelf product, standardized production that meets pre-defined quality standards, and potentially reduced costs. However, allo-CAR-T therapies encounter significant challenges, particularly the risk of graft-versus-host disease (GvHD), a clinically observed complication unless mitigating steps are taken, and host immune-mediated rejection, which can compromise their safety and effectiveness. Alternative approaches focus on gene-editing techniques and cell source modifications to maintain the efficacy of allo-CAR-Ts in hematologic malignancies while minimizing complications. Techniques such as CRISPR/Cas9-mediated disruption of TCR and HLA genes, the use of γδ T cells, and the overexpression of immunomodulatory proteins like CD47 offer promising strategies for creating safer and more effective CAR-T cell therapies. However, further research and clinical validation are necessary to optimize these approaches and minimize the risk of adverse immune reactions in patients. This review summarizes current advancements in gene editing, the use of CRISPR-Cas9 technology, innovations in lymphodepletion regimens, and strategies for overcoming graft rejection. We also dive into currently approved therapies, ongoing clinical trials, and future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesHumansTransplantation, HomologousGraft vs Host DiseaseReceptors, Antigen, T-CellGene Editing

Stichwörter der Autor:innen

AllogeneicCAR TCRISPRChimeric antigen receptor T cellHematologic malignancyImmunotherapy

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic Foundation, Fairview Hospital, Cleveland, Ohio. Electronic address: Cheemaa@ccf.org.
  • Department of Hematology and Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.
  • Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Department of Internal Medicine, University of Alabama, Birmingham, Alabama.
  • Department of Medicine, Shifa International Hospital, Islamabad, Pakistan.
  • Department of Medicine, Lahore Medical and Dental College, Lahore, Pakistan.

Zitieren

APA

Cheema, A. Y., Ali, H. M., Maryam, B., Aslam, M. F., Thiagarajan, P. S., Shahid, D., Munir, M., Najam, A., Raza, S., & Anwer, F. (2026). Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2025.09.044

Vancouver

Cheema AY, Ali HM, Maryam B, Aslam MF, Thiagarajan PS, Shahid D, et al. Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies. Transplantation and Cellular Therapy. 2026. doi:10.1016/j.jtct.2025.09.044

BibTeX
@article{Cheema2026,
  author = {Cheema, Asfand Yar and Ali, Hossam M and Maryam, Bibi and Aslam, Muhammad Faisal and Thiagarajan, Praveena S and Shahid, Daniyal and Munir, Mishaal and Najam, Ali and Raza, Shahzad and Anwer, Faiz},
  title = {Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies},
  journal = {Transplantation and Cellular Therapy},
  year = {2026},
  doi = {10.1016/j.jtct.2025.09.044}
}
Kostenlos starten →